Drug intelligence / Profile preview

RCYM-001

Development stage: Discontinued
Lead developer: Raynovent Biotech
Modality: Small Molecules

Overview

RCYM-001 is a small molecule drug that was initially developed by RAYNOVENT. It was investigated for the treatment of digestive system disorders, with nonalcoholic steatohepatitis (NASH) listed as an inactive indication. The drug reached preclinical development but has since been discontinued, and no further clinical or mechanistic details are publicly available[1].

Beyond the preview

Go deeper on RCYM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCYM-001.

Explore the full profile